Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. (Q38209572)

31 August 2017

title

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. (English)

1 reference

B-cell chronic lymphocytic leukemia

31 August 2017

0 references

1 reference

2

1 reference

31 August 2017

Giovanni D'Arena

1

1 reference

31 August 2017

Silvia Deaglio

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

6 May 2014

1 reference

Expert Opinion on Therapeutic Patents

31 August 2017

published in

1 reference

31 August 2017

volume

24

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

821-828

1 reference

CD44: from adhesion molecules to signalling regulators

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

The normal structure and function of CD44 and its role in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

21 January 2018

The liberation of CD44.

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Hyaluronan-CD44 interactions as potential targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Expression and modulation of CD44 variant isoforms in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Forms and functions of CD44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Receptor-ligand interaction between CD44 and osteopontin (Eta-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Rheostatic signaling by CD44 and hyaluronan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Expression of CD44 is repressed in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Role of CD44 in tumour progression and strategies for targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 signaling through p56lck involves lateral association with CD4 in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 ligation with A3D8 antibody induces apoptosis in acute myeloid leukemia cells through binding to CD44s and clustering lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 ligation induces apoptosis via caspase- and serine protease-dependent pathways in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathway in human erythroleukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Ligation of CD44 with low-molecular-weight hyaluronan and a monoclonal antibody leads to inhibition of drug-induced apoptosis in a human myeloid cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

4 1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.915942

10.1517/13543776.2014.915942

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference